Drugs / BD03
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03576014 | Apr 2018 → Jan 2019 | BK-virus nephropathy, idiopathic disseminated cytomegalovirus infection, polyomavirus infectious disease | SL VAXiGEN | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BD03 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03576014 ↗ |
| Modality | Vaccine | “BD03 is a DNA vaccine” NCT03576014 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT03576014 ↗ |